AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01946789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.
Study NCT00905424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (lisdexamfetamine dimesylate)
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
Study NCT00905424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + placebo
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
Study NCT01681953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study NCT01681953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusions weekly
Study NCT03126461 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SAbR
Description: For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose.
Study NCT03126461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 3mg/kg IV q3wk x 4
Study NCT03126461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 1 mg/kg IV q3wk x 4
Study NCT00438204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
Study NCT00438204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
Study NCT00438204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
Study NCT02306850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
Study NCT06190600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: HIIT training twice a week throughout the chemotherapy: treadmill, elliptical, stationary bicycle and indoor rower. The intensity of physical activity will be increasing during consecutive mesocycles. Each training session will begin with a 10-min. wole-body warm-up session at 50-60% hear rate (HR) max. Mesocycle 1 - one month with 4 sets of 1 min. 45 sec. of exercise at a maximal intensity of 75% HR max. Mesocycle 2 with exercises at 80% to 90% HR max divided into 3 periods: 1/ one month, session of 5 sets 1 min. 30 sec. each; 2/ two months, sessions of 5 sets 1 min. 45 sec. each; 3/ two months, sessions of 5 sets 2 min. each. Moreover patients will be instructed to individually perform- a 45-min. aerobic training session (e.g.: walking, jogging, roller skating, swimming) once a week, in patient's own time.
Study NCT06190600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)
Description: Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
Study NCT06190600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)
Description: Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
Study NCT06190600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Supportive Care
Description: Patients will be asked to perform 150-300 min. of moderate-intensity aerobic activity or 75-150 min. of vigorous aerobic activity. Each participant will be monitored by an activity watch worn at all times by the patient.
Study NCT01922258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole, OPC-34712
Description: Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
Study NCT01922258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brexpiprazole, OPC-34712
Description: Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
Study NCT02506699 — intervention group
Intervention type: OTHER
Intervention: analgesic effect of rTMS
Study NCT01007604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peristaltic pulse PCD
Description: Daily use for two hours
Study NCT01007604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and lifestyle counseling
Description: Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
Study NCT02820519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxapine
Description: Loxapine dose escalation according to tolerability and analgesic efficacy
Study NCT02472886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT00539591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Given either IV or SQ. Therapeutic drug class: interferon.
Study NCT00539591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO. Therapeutic drug class: antineoplastic agent.
Study NCT00539591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2b
Description: Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
Study NCT03924635 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SYMBICORT and salbutamol
Description: SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
Study NCT02472886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT00770913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E3810
Description: 20 mg taken orally, once a day for 8 weeks.
Study NCT00770913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: 10 mg, taken orally, twice a day for 8 weeks.
Study NCT00770913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: 20 mg taken orally, twice a day for 8 weeks.
Study NCT00382785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderated support
Description: one 12-week online support group led by a professional healthcare provider
Study NCT00382785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-led
Description: 12-week online support in a peer-led format
Study NCT01074177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: Taken orally once a day
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 6
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 12
Description: Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 6
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 12
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 30
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT03180268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Undergo observation
Study NCT03180268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04097145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
Study NCT04097145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal Medical Therapy alone in patients with tricuspid regurgitation
Study NCT04097145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter tricuspid valve repair with the Edwards PASCAL System in conjunction with OMT
Study NCT04097145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter tricuspid valve repair with the Edwards PASCAL system in patients on optimal medical therapy (OMT) with tricuspid regurgitation
Study NCT01218854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle angle measurement
Description: The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
Study NCT00843882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT00843882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT00843882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Given SC
Study NCT00843882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00843882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00843882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO
Study NCT00843882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02074293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox subdermally
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT04290806 — intervention group
Intervention type: OTHER
Intervention: Routine care as per site standard
Description: Physician's choice according to patient's needs. Routine care as per site standard.
Study NCT03173235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma level of vitamin D
Description: messurement of plasma level of vitamin D
Study NCT03406351 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational deep phenotyping physiological readouts
Study NCT00712894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Intracoronary Infusion 400-2000ug
Study NCT00712894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Intracoronary Infusion 200-1000ug
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Examination of vibration perception threshold in fingertips
Description: Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ewing's tests
Description: A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
Study NCT00712894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Intracoronary Infusion 200-1000ug
Study NCT02710084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table test
Description: Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Thermography
Description: An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 123I-MIBG
Description: 123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
Study NCT03094910 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines.
Study NCT03901014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard American diet
Description: Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
Study NCT03901014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Ketogenic diet with \<50g carbohydrate, 60-75% energy from fat, and 20% from protein
Study NCT00493571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Starting dose: 0.6 mg capsules administered orally once daily.
Study NCT02663596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
Study NCT00299156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
Study NCT03996486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
Study NCT02540356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 Single-Route Arm
Description: Intraperitoneal (IP) only
Study NCT02540356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 Double-Route Arm
Description: Intravenous (IV) infusion + intraperitoneal (IP) infusion